1. Clinical & Scientific Overview
Enalapril Maleate (TIP-MED-000006, Reference Code [3.6]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted to Enalaprilat).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Envas (Cadila), Enam (Dr. Reddy's), BQL (Alkem)
Oral Uncoated Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg
3. Mechanism of Action & Pharmacodynamics
Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted to Enalaprilat) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted to Enalaprilat) for Hypertension; symptomatic heart failure (HFrEF); asymptomatic left ventricular dysfunction (EF ≤35%)..
4. Therapeutic Indications & Evidence-Supported Uses
- Hypertension
- symptomatic heart failure (HFrEF)
- asymptomatic left ventricular dysfunction (EF ≤35%)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Hypertension: Initially 5 mg OD (2.5 mg if on diuretics or renal impairment), maintenance 10–20 mg/day in 1–2 divided doses (max 40 mg/day). Heart Failure: Start 2.5 mg OD/BD, titrate gradually to target 10–20 mg BD. Follow physician prescription.
Administration & Meal Timing: With or without food (absorption is unaffected by food). | First dose at bedtime; maintenance doses in the morning (if OD) or morning and evening (12 hours apart if BD).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Dosing strictly depends on renal function! If CrCl 30–80 mL/min, start at 2.5–5 mg/day; if CrCl <30 mL/min, start at 2.5 mg once daily and titrate cautiously based on K+ and creatinine. Dialysable (give 2.5 mg on dialysis days). Hepatic: Delayed prodrug activation in severe cirrhosis; monitor closely.
Renal: Dosing strictly depends on renal function! If CrCl 30–80 mL/min, start at 2.5–5 mg/day; if CrCl <30 mL/min, start at 2.5 mg once daily and titrate cautiously based on K+ and creatinine. Dialysable (give 2.5 mg on dialysis days). Hepatic: Delayed prodrug activation in severe cirrhosis; monitor closely.
Renal: Dosing strictly depends on renal function! If CrCl 30–80 mL/min, start at 2.5–5 mg/day; if CrCl <30 mL/min, start at 2.5 mg once daily and titrate cautiously based on K+ and creatinine. Dialysable (give 2.5 mg on dialysis days). Hepatic: Delayed prodrug activation in severe cirrhosis; monitor closely.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in pregnancy, history of angioedema, bilateral renal artery stenosis, and within 36 hours of sacubitril/valsartan. Caution in aortic stenosis and collagen vascular diseases.
Key Clinical Precautions: Renal: Dosing strictly depends on renal function! If CrCl 30–80 mL/min, start at 2.5–5 mg/day; if CrCl <30 mL/min, start at 2.5 mg once daily and titrate cautiously based on K+ and creatinine. Dialysable (give 2.5 mg on dialysis days). Hepatic: Delayed prodrug activation in severe cirrhosis; monitor closely.
8. Adverse Effects Profile
- Dry persistent cough (bradykinin-mediated), postural dizziness, headache, orthostatic hypotension, mild hyperkalaemia, taste alteration.
- Angioedema of face/larynx, severe hyperkalaemia, acute kidney injury, cholestatic jaundice, neutropenia.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Spironolactone, amiloride, potassium chloride, and trimethoprim increase risk of fatal hyperkalaemia
- NSAIDs antagonise antihypertensive effect and precipitate renal failure
- Increases serum lithium and enhances hypoglycaemic sensitivity to insulin/sulfonylureas
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Rise slowly from lying or sitting positions. Do not self-medicate with cough syrups for a persistent dry cough; inform the doctor at the next OPD visit. Report facial/lip swelling or reduced urine output immediately.
- Meal & Clock Timing Instruction: With or without food (absorption is unaffected by food). (First dose at bedtime; maintenance doses in the morning (if OD) or morning and evening (12 hours apart if BD).)
- Missed Dose Protocol: Take as soon as remembered unless almost time for the next dose; never double the dose.
- Geriatric Dispensing Pearl: Because enalaprilat has a shorter duration of action than ramiprilat in some patients, twice-daily dosing (e.g., 2.5 mg or 5 mg BD) is common in heart failure. Check serum potassium regularly when co-prescribed with spironolactone in elderly HFrEF patients.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.6] (p. 23)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.8] Atenolol — Hydrophilic Cardioselective Beta-1 Adrenergic Blocker
- [3.9] Carvedilol — Non-Selective Beta-1/Beta-2 and Alpha-1 Adrenergic Blocker; Antio
- [3.10] Bisoprolol Fumarate — Highly Cardioselective Beta-1 Adrenergic Blocker
- [3.11] Chlorthalidone — Thiazide-Like Diuretic (Long-Acting Sulfonamide Derivative)
